Login to Your Account



MediGene Pads Coffers, Inks $17.7M Eligard Royalty Deal

By Marie Powers
Staff Writer

Wednesday, June 13, 2012
MediGene AG became the latest biotech to choose a royalty deal over other financing options to bolster its bottom line. Last week, the company transferred its 2 percent royalty share of European net sales in prostate cancer drug Eligard (leuprolide acetate) to Cowen Healthcare Royalty Partners II LP for $17.7 million in cash.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription